Neuroinflammation, marked by gliosis and infiltrating T cells, is a prominent pathological feature in diverse models of dominantly inherited neurodegenerative diseases. Recent evidence derived from transgenic mice ubiquitously overexpressing mutant Cu 2؉ / Zn 2؉ superoxide dismutase (mSOD1), a chronic neurodegenerative model of inherited amyotrophic lateral sclerosis (ALS), indicates that glia with either a lack of or reduction in mSOD1 expression enhance motoneuron protection and slow disease progression. However, the contribution of T cells that are present at sites of motoneuron injury in mSOD1 transgenic mice is not known. Here we show that when mSOD1 mice were bred with mice lacking functional T cells or CD4؉ T cells, motoneuron disease was accelerated, accompanied by unexpected attenuated morphological markers of gliosis, increased mRNA levels for proinflammatory cytokines and NOX2, and decreased levels of trophic factors and glial glutamate transporters. Bone marrow transplants reconstituted mice with T cells, prolonged survival, suppressed cytotoxicity, and restored glial activation. These results demonstrate for the first time in a model of chronic neurodegeneration that morphological activation of microglia and astroglia does not predict glial function, and that the presence of CD4؉ T cells provides supportive neuroprotection by modulating the trophic/cytotoxic balance of glia. These glial/T-cell interactions establish a novel target for therapeutic intervention in ALS and possibly other neurodegenerative diseases.
D
ysfunction or death of specific neuronal populations most at risk for dominantly inherited neurodegenerative diseases is not mediated solely by the expression of the mutant protein within target neurons (1) . Dominant mutations in the Cu 2ϩ /Zn 2ϩ superoxide dismutase (mSOD1) gene are the most frequent cause of inherited amyotrophic lateral sclerosis (ALS), an inexorably progressive and fatal neuromuscular disease, and current evidence suggests that motoneuron injury is nonϪ cell-autonomous and involves damage caused by mSOD1 proteins within glia of the central nervous system (CNS) (1Ϫ 4). Reduced mSOD1 protein levels in astroglia have been shown to delay microglial activation and to sharply slow disease progression (5) . Eliminating or reducing mSOD1 expression from microglia also slows motoneuron loss and disease progression (6, 7) . Although neuroinflammation is a pathological hallmark in transgenic mice ubiquitously overexpressing mSOD1 (8, 9) , the role of T cells in this model of chronic neurodegeneration is not understood; however, they have been shown to modulate microglial activation and provide neuroprotection in acute models of neuronal injury (10Ϫ16). Thus, to assess the role of T cells in a chronic neurodegenerative disease such as ALS, immunodeficient mice were bred with mSOD1 G93A transgenic mice and selective reconstitution experiments with bone marrow transplants (BMT) were used to elucidate the roles of T cells. These studies provide compelling evidence that the presence of CD4ϩ T cells, either directly or indirectly, morphologically and functionally alter microglial and astroglial activation, and may support neuroprotection by modulating the glial balance between trophism and cytotoxicity.
Results CCR2 ؊/؊ Donor Cells Are Not Neuroprotective. To examine possible contributions of the peripheral immune system on disease progression, mSOD1 G93A /PU.1 Ϫ/Ϫ mice on a B6/SJL genetic background [supporting information (SI)] received BMT from CCR2 Ϫ/Ϫ mice lacking the receptor for monocyte-chemoattractant proteinϪ1 (MCP-1/CCL2) (6) . MCP-1 recruits CCR2-expressing cells, including activated T cells and monocytes, to sites of injury (17, 18) and is increased in mSOD1 G93A mice (19) . Although mean onset times were not different between groups (SI Text, Fig. S1 ), mSOD1 G93A / PU.1 Ϫ/Ϫ mice receiving CCR2 Ϫ/Ϫ BMT had shorter life spans and disease durations than mSOD1 G93A /PU.1 Ϫ/Ϫ mice transplanted with wild-type (WT) bone marrow (survival, P ϭ 0.026; duration, P ϭ 0.032), similar to mSOD1 G93A /PU.1 Ϫ/Ϫ mice transplanted with mSOD1 G93A bone marrow and mSOD1 G93A /PU.1 ϩ/Ϫ littermates ( Fig. 1 A and B) . With the exception of expressing CCR2, the engrafted microglia were WT and yet demonstrated less immunohistochemical evidence of morphological activation than mice transplanted with WT bone marrow ( Fig. 1C and D) . Unlike mSOD1 G93A /PU.1 Ϫ/Ϫ mice that received mSOD1 G93A or WT BMT, CD3ϩ T cells were not observed in mSOD1 G93A /PU.1 Ϫ/Ϫ mice with CCR2 Ϫ/Ϫ BMT ( Fig. 1 E and F).
T and/or B Cells Contribute to Neuroprotection. The significance of infiltrating lymphocytes were assayed by breeding mSOD1 G93A mice with recombination-activating gene 2 knockout (RAG2 Ϫ/Ϫ ) mice that lack functional T and B cells (20) . Although onset times were not different (Fig. S2 ), mSOD1 G93A /RAG2 Ϫ/Ϫ mice on a C57BL/6 genetic background (SI Text) had shorter life spans and disease durations than mSOD1 G93A /RAG2 ϩ/Ϫ littermates (mean survival, P ϭ 0.00001; duration, P ϭ 0.00001) ( Fig. 1G and H) , suggesting T and/or B cells contribute to neuroprotection. To determine whether RAG2 has unknown CNS functions, sublethally ␥-irradiated mSOD1 G93A /RAG2 Ϫ/Ϫ mice were reconstituted with functional T and B cells by BMT from either mSOD1 G93A or WT mice. Transplanted mSOD1 G93A /RAG2 Ϫ/Ϫ mice survived longer with a slower disease progression than non-transplanted mSOD1 G93A /RAG2 Ϫ/Ϫ mice (mSOD1 G93A : survival, P ϭ 0.00004 and duration, P ϭ 0.0016; WT: survival, P ϭ 0.001 and duration, P ϭ 0.0025), similar to mSOD1 G93A /RAG2 ϩ/Ϫ mice ( Fig. 1G and H, and Fig. S2 ). Because lethal ␥-irradiation with 1100 cGy may artificially induce circulating myeloid cells to infiltrate the CNS (21, 22) , the mice in this study received sublethal 400 cGy ␥-irradiation treatments. This dose of ␥-irradiation did not induce additional myeloid cell infiltration into the CNS (data not shown). However, to ensure that the increased survival was not caused by additional leukocytes and the radiation treatment, sublethally ␥-irradiated mSOD1 G93A /RAG2 Ϫ/Ϫ mice received BMT from RAG2 Ϫ/Ϫ mice that have normal functioning monocytes/macrophages, neutrophils, etc (20) . Survival times of mSOD1 G93A /RAG2 Ϫ/Ϫ mice receiving RAG2 Ϫ/Ϫ BMT were similar to non-transplanted mSOD1 G93A / RAG2 Ϫ/Ϫ mice, but shorter survival times and disease durations than mSOD1 G93A /RAG2 Ϫ/Ϫ mice transplanted with either mSOD1 G93A or WT bone marrows (mSOD1 G93A : survival, P ϭ 0.0001 and duration, P ϭ 0.003; WT: survival, P ϭ 0.001 and duration, P ϭ 0.005) ( Fig. 1G and H, and Fig. S2 ).
T and/or B Cells Influence the Rate of Disease Progression. Rates of disease progression (6) were different at 11 weeks of age when mSOD1 G93A /RAG2 Ϫ/Ϫ mice were compared with mSOD1 G93A / RAG2 ϩ/Ϫ mice (P ϭ 0.0006) and further diverged between 14 and 18 weeks, a time at which disease progression plateaued in mSOD1 G93A /RAG2 ϩ/Ϫ mice ( Fig. 1I ) (23) . Following BMT with mSOD1 G93A cells, mSOD1 G93A /RAG2 Ϫ/Ϫ mice had a similar 4 week latency progression profile as mSOD1 G93A /RAG2 ϩ/Ϫ mice.
Presence of T-Cells Is Restored After BMT. Using CD3, a pan T-cell marker, CD4, and CD8 antibodies, the presence of T cells were examined in lumbar spinal cords from 75 (disease onset), 105 (the plateau phase), and 140 (the declining performance phase) day old mice, and at end-stage disease (Fig. 2 A-D and Fig. S3A-D) . No , and were similar to mSOD1 G93A /PU.1 ϩ/Ϫ littermates (133 Ϯ 2 days, n ϭ 12; data not shown for clarity) and mSOD1 G93A /PU.1 Ϫ/Ϫ mice with mSOD1 G93A BMT (130 Ϯ 2 days, n ϭ 12). (B) Disease duration was attenuated in mSOD1 G93A /PU.1 Ϫ/Ϫ mice receiving CCR2 Ϫ/Ϫ BMT. Data for mSOD1 G93A / PU.1 ϩ/Ϫ mice were eliminated for clarity but were similar to mSOD1 G93A / PU.1 Ϫ/Ϫ mice with mSOD1 G93A BMT (P ϭ 0.55). (C) CD11b immunohistochemistry of morphologically activated microglia at end-stage disease in mSOD1 G93A /PU.1 ϩ/Ϫ mice. (D) Following BMT with CCR2 Ϫ/Ϫ donor-derived cells, the CD11b signal from microglia of mSOD1 G93A /PU.1 Ϫ/Ϫ was reduced. (E) CD3ϩ T cells were observed in mSOD1 G93A /PU.1 ϩ/Ϫ mice. (F) CD3ϩ T cells were absent in mSOD1 G93A /PU.1 Ϫ/Ϫ mice receiving CCR2 Ϫ/Ϫ BMT. (G) Survival times were shorter in mSOD1 G93A /RAG2 Ϫ/Ϫ mice, on a C57BL/6 genetic background, lacking functional T and B cells (145 Ϯ 2 days, n ϭ 14) than in mSOD1 G93A / RAG2 ϩ/Ϫ littermates (161 Ϯ 2 days, n ϭ 13), but were prolonged following BMT (mSOD1 G93A : 164 Ϯ 3 days, n ϭ 10; WT: 161 Ϯ 2 days, n ϭ 10). RAG2 Ϫ/Ϫ BMT did not increase survival (148 Ϯ 2 days, n ϭ 10). Survival of mSOD1 G93A /RAG2 ϩ/Ϫ mice were similar to mSOD1 G93A /RAG2 ϩ/ϩ (160 Ϯ 3 days, n ϭ 20, P ϭ 0.61). (H) Disease duration was shorter in mSOD1 G93A /RAG2 Ϫ/Ϫ mice than mSOD1 G93A / RAG2 ϩ/Ϫ littermates, but was prolonged following BMT. (I) Disease progression in mSOD1 G93A /RAG2 Ϫ/Ϫ mice lacked the 4-week plateau of mSOD1 G93A / RAG2 ϩ/Ϫ mice and was re-established after mSOD1 G93A BMT. G93A transgenic mice were bred with CD4 knockout (CD4 Ϫ/Ϫ ) mice that lack surface expression of CD4, but have unaltered myeloid-, CD8ϩ T and B cells (24) . Although disease onset was not different (Fig. S4A) , survival of mSOD1 G93A / CD4 Ϫ/Ϫ mice was shorter than mSOD1 G93A /CD4 ϩ/Ϫ littermates (P ϭ 0.001) (Fig. 2F) (Fig. 3 A-C and G-I and Fig.  S5A-I 
and J).
To address the question of whether all glial responses were reduced, astroglial morphology was evaluated in lumbar spinal cords. At end-stage disease, GFAP immunoreactivity was increased in transgenic mice compared with WT mice (Fig. 3M-O ). This increase was confirmed using quantitative RT-PCR for GFAP (Fig.  4B ). Furthermore, both qualitatively and quantitatively, there were no differences in the expression of GFAP between any transgenic mouse line or after BMT (Fig. 3P ). At 105 days of age, mSOD1 G93A / RAG2 Ϫ/Ϫ mice had reduced GFAP signal compared to mSOD1 G93A /RAG2 ϩ/Ϫ mice and BMT restored the GFAP immunoreactivity ( Fig. 3Y-AA) . GFAP immunoreactivity was observably less at 75 days of age in sections from mSOD1 G93A /RAG2 Ϫ/Ϫ mice compared with sections from mSOD1 G93A /RAG2 ϩ/Ϫ mice ( Fig.  S5N and O) .
Immunohistochemical evaluation of microglia in lumbar spinal cords of mSOD1 G93A /CD4 Ϫ/Ϫ mice showed a similar attenuation of CD11b and CD68 signal as observed in mSOD1 G93A /RAG2 Ϫ/Ϫ mice ( Fig. 3E , F, K, and L). Quantitative RT-PCR confirmed that the message for CD68 in lumbar spinal cords was reduced in mSOD1 G93A /CD4 Ϫ/Ϫ mice (P ϭ 0.03) (Fig. 4A ). However, unlike the astrogliosis noted at end-stage disease for mSOD1 G93A / RAG2 Ϫ/Ϫ mice, there was an observable reduction in GFAP immunoreactivity in mSOD1 G93A /CD4 Ϫ/Ϫ mice compared with mSOD1 G93A /CD4 ϩ/Ϫ mice ( Fig. 3Q and R). Although CD4ϩ and CD8ϩ T cells were observed in mSOD1 G93A /CD4
ϩ/Ϫ mice (data 
Immunohistochemical evaluations of lumbar spinal cord. The CD11b microglial/macrophage signal observed at end-stage disease in lumbar spinal cord sections of mSOD1 G93A /RAG2 ϩ/Ϫ mice (A) was decreased in mSOD1 G93A /RAG2 Ϫ/Ϫ mice (B) and restored after mSOD1 G93A BMT (C). CD11b signal was not restored after RAG2 Ϫ/Ϫ BMT (D). As with mSOD1 G93A /RAG2 Ϫ/Ϫ mice, the CD11b immunoreactivity observed at end-stage disease in mSOD1 G93A /CD4 ϩ/Ϫ mice (E) was reduced in mSOD1 G93A /CD4 Ϫ/Ϫ mice (F). Similar results were observed with antibodies to CD68 (G-L), which was consistent with the quantitative RT-PCR results. GFAP immunoreactivity was not different between groups at end-stage disease (M-O) and was unchanged after RAG2 Ϫ/Ϫ BMT (P). The GFAP signal observed in mSOD1 G93A /CD4 ϩ/Ϫ mice (Q) was less in mSOD1 G93A /CD4 Ϫ/Ϫ mice (R). Compared with that observed with CD11b staining of mSOD1 G93A /RAG2 ϩ/Ϫ mice at 105 days of age (S), microglial activation was less in mSOD1 G93A /RAG2 Ϫ/Ϫ mice at the same age (T) and again restored following mSOD1 G93A BMT (U). Similar results were observed with CD68 at 105 days of age (V-X). Compared with mSOD1 G93A /RAG2 ϩ/Ϫ mice at 105 days of age (Y), astrocyte activation was reduced in mSOD1 G93A /RAG2 Ϫ/Ϫ mice at 105 days of age (Z) and restored after mSOD1 G93A BMT (AA). not shown), CD8ϩ T cells were observed only at end-stage disease in mSOD1 G93A /CD4 Ϫ/Ϫ mice (Fig. 2D ).
Microglia From Mice Lacking T-Cells Are Not Dysfunctional.
To ensure that the morphological reduction of microglia activation in mSOD1 G93A /RAG2 Ϫ/Ϫ mice was not caused by an inherent dysfunction of the microglia, in vitro cultures of microglia from RAG2 Ϫ/Ϫ mice were compared with microglia from WT mice for their ability to undergo morphological and functional activation. Following lipopolysaccharide (LPS) treatment, a treatment known to increase the release of tumor necrosis factor-␣ (TNF-␣) and interleukin-1␤ (IL-1␤), there were no differences in the production of TNF-␣ or IL-1␤ between microglia isolated from RAG2 Ϫ/Ϫ mice compared with WT mice at any dose of LPS ( Fig. S6A and B) . Morphologically, there were also no differences between LPStreated RAG2 Ϫ/Ϫ microglia and LPS-treated WT microglia (data not shown). Thus, activated microglia from RAG2 Ϫ/Ϫ mice are morphologically and functionally similar to activated WT microglia.
The Presence of CD4؉ T-Cells Enhances Neuroprotection and Sup-
presses Cytotoxic Factors. mRNAs for the neurotrophic factors IGF-1 and GDNF were quantitatively decreased in the lumbar spinal cords of mSOD1 G93A /RAG2 Ϫ/Ϫ mice compared with mSOD1 G93A and mSOD1 G93A /RAG2 ϩ/Ϫ mice and were similar to levels in WT mice ( Fig. 4C and D) . The mRNA for BDNF was decreased in both mSOD1 G93A and mSOD1 G93A /RAG2 ϩ/Ϫ mice but was further decreased in mSOD1 G93A /RAG2 Ϫ/Ϫ mice (Fig. 4E) . BMT of mSOD1 G93A /RAG2 Ϫ/Ϫ mice with mSOD1 G93A donorderived cells restored the levels of IGF-1, GDNF, and BDNF to those of mSOD1 G93A /RAG2 ϩ/Ϫ mice. Levels of these trophic factors were similar between mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice. In contrast, the mRNA expression for NGF was not different between WT mice and any genotype of mSOD1 G93A mice in this study (Fig. S7A ). mRNA levels for several glutamate transporters, which are known to affect motoneuron viability, also paralleled survival (25, 26) . Expression of GLT-1 and GLAST mRNAs was decreased in mSOD1 G93A /RAG2
Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice ( Fig. 4F and G); GLAST mRNA levels were similar to levels in WT mice. BMT of mSOD1 G93A /RAG2 Ϫ/Ϫ mice with mSOD1 G93A donorderived cells restored the levels of GLT-1 and GLAST mRNA to those of mSOD1 G93A /RAG2 ϩ/Ϫ mice. EAAC1 mRNA levels were decreased in mSOD1 G93A , mSOD1 G93A /RAG2 ϩ/Ϫ , mSOD1 G93A / RAG2 Ϫ/Ϫ , and mSOD1 G93A /CD4 Ϫ/Ϫ mice compared with WT mice, and BMT of mSOD1 G93A /RAG2 Ϫ/Ϫ mice did not alter EAAC1 levels in these mice (Fig. S7B) .
The mRNA levels of IL-4 and TGF-␤, two anti-inflammatory factors, were increased in mSOD1 G93A and mSOD1 G93A /RAG2
ϩ/Ϫ mice compared with WT mice (Fig. 4H and I) but were decreased in mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice; BMT restored IL-4 and TGF-␤ levels to levels observed in mSOD1 G93A and mSOD1 G93A /RAG2 ϩ/Ϫ mice. The expression of Ym1 mRNA mirrored the IL-4 results across all genotypes of mSOD1 G93A mice, suggesting a loss of alternatively activated macrophages that are involved in resolving inflammation and promoting wound healing (Fig. S7C) (27) . Fractalkine receptor (CX3CR1), expressed on microglia, monocytes, dendritic cells, and subsets of T cells, which has been shown to decrease microglial toxicity possibly by regulating the release of cytotoxic substances (28) , was reduced in mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice (Fig. S7D ). BMT in mSOD1 G93A /RAG2 Ϫ/Ϫ restored Ym1 and CX3CR1 mRNA to levels seen in mSOD1 G93A and mSOD1 G93A /RAG2 ϩ/Ϫ mice. TNF-␣ mRNA levels were increased in mSOD1 G93A and mSOD1 G93A /RAG2 ϩ/Ϫ mice compared with WT mice, and were further elevated in mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A / CD4 Ϫ/Ϫ mice (Fig. 4J ). IL-6 was not increased in mSOD1 G93A or mSOD1 G93A /RAG2 ϩ/Ϫ mice compared with WT mice, but was increased in mSOD1 G93A /RAG2 Ϫ/Ϫ mice (Fig. S7E ). IL-6 expression was not elevated in mSOD1 G93A /CD4 Ϫ/Ϫ mice, with levels similar to WT and mSOD1 G93A mice, possibly because of the presence of functional B cells in these mice. BMT reduced the TNF-␣ and IL-6 mRNA levels to those seen in mSOD1 G93A or mSOD1 G93A /RAG2 ϩ/Ϫ mice. TNF-␣ receptors I and II, iNOS, and IL-1␤ mRNA levels were not different in any of the genotypes of mSOD1 G93A mice studied (Fig. S7F-I ). The mRNA level for GFAP was increased in all mSOD1 G93A groups of mice. (C-E) There were reduced message levels for IGF-1, GDNF, and BDNF in mSOD1 G93A /RAG2 Ϫ/Ϫ mice compared with mSOD1 G93A /RAG2 ϩ/Ϫ mice at end-stage disease, and the levels were restored after mSOD1 G93A BMT. Message levels for these neurotrophic factors were also reduced in mSOD1 G93A /CD4 Ϫ/Ϫ mice. Similar results were obtained for GLT-1 (F) and GLAST (G), glutamate transporters predominately localized on astrocytes. (H) IL-4 was reduced in mSOD1 G93A / RAG2 Ϫ/Ϫ mice compared with mSOD1 G93A / RAG2 ϩ/Ϫ mice, but was restored following mSOD1 G93A BMT. mSOD1 G93A /CD4 Ϫ/Ϫ mice also had a reduced mRNA level for IL-4. (I) TGF-␤, an anti-inflammatory/neurotrophic factor, was decreased in mSOD1 G93A /RAG2 Ϫ/Ϫ mice compared with mSOD1 G93A /RAG2 ϩ/Ϫ mice but was again restored following mSOD1 G93A BMT. (J) In contrast to IL-4 and TGF-␤, the proinflammatory agent TNF-␣ was elevated in mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice. (K) NOX2, a subunit in the enzyme responsible for the production of highly toxic superoxide molecules, was also elevated in mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice. ϩIncreased compared with WT mice, P Ͻ 0.05;
The NADPH oxidase isoform NOX2 mRNA was elevated 70-fold in mSOD1 G93A and mSOD1 G93A /RAG2 ϩ/Ϫ mice compared with WT mice, and was increased 110-fold in mSOD1 G93A / RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice (Fig. 4K) . BMT in mSOD1 G93A /RAG2 Ϫ/Ϫ mice reduced the NOX2 mRNA levels to those seen in mSOD1 G93A or mSOD1 G93A /RAG2 ϩ/Ϫ mice. The increased expression of proinflammatory cytokines and NOX2 does not lead to increased mouse or mutant human SOD1 mRNA expression, indicating that the shortened survival times are not caused by enhanced SOD1 mRNA expression (Fig. S7J and K) (29, 30) .
Discussion
Immune dysfunction is a pathological feature in human ALS and mSOD1 transgenic mice (31) . Because T cells are present at sites of motoneuron injury (9) and their role in injury is not known, this study directly addressed whether T cells contribute to the disease process of mSOD1 G93A -initiated chronic motoneuron degeneration. The results establish that the lack of T-cell recruitment, either through the loss of CCR2 or developmental inhibition, accelerates disease progression and the demise of these mice. These studies demonstrate for the first time that CD4ϩ T cells, directly or indirectly, are possibly the subpopulation of T cells that are neuroprotective in this model of inherited chronic neurodegeneration.
To determine whether recruitment of peripheral immune cells and/or microglia is essential for neuroprotection, mSOD1 G93A / PU.1 Ϫ/Ϫ mice received BMT from CCR2 Ϫ/Ϫ donor mice. Although onset of disease was not altered, disease progression was accelerated. In addition, these mice lacked CD3ϩ T cells and morphologically activated microglia, which were observed in mSOD1 G93A / PU.1 Ϫ/Ϫ mice transplanted with mSOD1 G93A or WT bone marrow. Acceleration of disease after CCR2 Ϫ/Ϫ BMT suggests that recruitment of microglia/monocytes and/or lymphocytes is involved in the pathogenesis of motoneuron injury, possibly by modulating glial function. A similar outcome was noted in a transgenic mouse model of Alzheimer disease, in which CCR2 deficiency accelerated disease progression and impaired microglial accumulation (18) .
To dissociate the effects of microglia/myeloid cell recruitment from lymphocyte recruitment as mediators of disease progression, mSOD1 G93A /RAG2 Ϫ/Ϫ mice were developed. Although disease onset was not altered, the lack of functional lymphocytes accelerated disease progression in mSOD1 G93A /RAG2 Ϫ/Ϫ mice. These data demonstrate, in a chronic neurodegenerative disease model, that lymphocytes are possibly needed for neuroprotection and microglial morphological activation. Although two recent reports suggest that 1100 cGy ␥-irradiation dose may artificially induce circulating myeloid cells to infiltrate the CNS (21, 22) , following a sublethal 400-cGy dose, spinal cord sections from mSOD1 G93A / RAG2 Ϫ/Ϫ mice transplanted with GFPϩ donor-derived bone marrow contained only GFPϩ lymphocytes; no GFPϩ cells with myeloid cell morphologies were present (data not shown). Furthermore, these previous studies did not report on the recruitment or infiltration of T cells into the CNS after lethal ␥-irradiation treatment. In this study, the composition of T-cell subpopulations was similar between mSOD1 G93A /RAG2 ϩ/Ϫ mice and ␥-irradiated mSOD1 G93A /RAG2 Ϫ/Ϫ mice after BMT; the number and subtypes of T cells was not altered because of ␥-irradiation treatment. Nevertheless, to rule out the possibility that irradiation, myeloid cells, or other leukocytes influenced disease onset, survival, or duration, mSOD1 G93A /RAG2 Ϫ/Ϫ mice were transplanted with RAG2 Ϫ/Ϫ derived bone marrow, and no beneficial effects were noted. In addition, WT and mSOD1 G93A bone marrow cells have equivalent neuroprotective abilities to prolong survival, possibly by modulating glial function. A possible explanation for these equivalent effects is that the donor-derived bone marrow precursor T cells are ''educated'' by the recipient's own local immune environment and, regardless of the T-cell genotype, the host will direct the activation of these transplanted lymphocytes.
Because CD4ϩ T cells were observed in the spinal cord during all phases of disease, including disease onset and during the plateau phase, and CD8ϩ T cells were present only in the terminal stages, CD4ϩ T cells may represent the relevant neuroprotective subpopulation of lymphocytes that prolonged survival in transplanted mSOD1 G93A /RAG2 Ϫ/Ϫ mice. To test this hypothesis, mSOD1 G93A / CD4 Ϫ/Ϫ mice were generated and compared with their mSOD1 G93A /CD4 ϩ/Ϫ littermates, and although disease onset was not altered, disease progression in mSOD1 G93A /CD4 Ϫ/Ϫ mice was accelerated to the same extent as in mSOD1 G93A /RAG2 Ϫ/Ϫ mice. Thus, the CD4ϩ T cells that entered the spinal cord at sites of motoneuron injury appear to be neuroprotective (12, 14, 16) , whereas the CD8ϩ T cells present at end-stage disease are possibly associated with injury.
In mSOD1 G93A /RAG2 ϩ/Ϫ and BMT mSOD1 G93A /RAG2
Ϫ/Ϫ mice, the T cells were localized throughout the ventral gray matter. Although 5 to 10 T cells per section were observed in mSOD1 G93A / RAG2 ϩ/Ϫ mice between the disease onset and the plateau phase of disease progression, which later increased to 19 T cells per section, similar numbers and subtypes of T cells were observed in mSOD1 G93A /RAG2 Ϫ/Ϫ mice following BMT with either mSOD1 G93A or WT donor-derived cells. In contrast, although T cells are known to be present in the central nervous system of mice under normal conditions, their presence is a rare event. Thus, as has been previously reported (32) , even at these earlier time points, the documented presence of T cells may have a considerable impact on the area's local immune response and may alter the trophic versus toxic balance of glia in these areas of chronic CNS neurodegeneration. However, it is also possible that the neuroprotective benefits of T-lymphocytes may be amplified by their presence at the neuromuscular junction or contiguous with injured motoneuron axons.
CD4ϩ T cells have also been reported to influence survival in an acute facial motoneuron injury model, possibly related to CD4ϩ secretion of BDNF (12) . In that model, CD4ϩ T-cell-mediated neuroprotection was found to depend on both resident microglia and peripherally derived antigen-presenting cells (15) . The activation of microglia, which causes them to function as antigenpresenting cells and to express MHC class II proteins, is correlated with a better outcome following CNS injury (11) . Thus, the beneficial or destructive outcome of the local microglial response is determined by a well-controlled dialog between the innate and adaptive immune systems; and, under specific circumstances and with the correct stimulation, T cells are anti-inflammatory and protect motoneurons from degenerating. Furthermore, in conjunction with previous BMT data (6), the CCR2 Ϫ/Ϫ BMT and RAG2 Ϫ/Ϫ data suggest that disease progression is influenced by lymphocytes as well as by glia (5-7). Most significantly, these data indicate that CD4ϩ T cells, either directly or indirectly, are the subpopulation of T cells that may be responsible for prolonging survival in this model of neurodegeneration.
The activation states of microglia and astrocytes, with respect to protection versus toxicity, cannot be inferred solely from their morphologies. The conventional morphological markers for activation were attenuated in mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice; yet the mRNA for NOX2, which is known to enhance microglial release of reactive oxygen species (33), was elevated and contributed to more rapid disease progression and death. Thus, morphological (CD11b, CD68, GFAP) markers of glial ''activation'' do not accurately predict the functional (TNF-␣, NOX2) markers of ''activation.'' The apparent morphological reduction of microglial activation occurs early in disease, indicating that the presence of T cells may increase the morphological activation state and antigen presentation abilities of microglia and may contribute to increased survival. Although not different at end stage, these results also suggest that all glial responses are not attenuated and that an increased astroglial response at earlier time points is neuroprotective. Furthermore, the data suggest that disease progression may be influenced by lymphocytes indirectly or possibly even directly, interacting with glia, balancing the trophic versus cytotoxic responses of microglia and astroglia. CD4ϩ T cells should now be included in the non-cell-autonomous hypothesis of neuroprotection (1) .
The shortened length of survival in mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice is partly due to decreased levels of neurotrophic factors and the reduced abilities of glia to remove glutamate, thus enhancing motoneuron excitotoxicity. Not only are neurotrophic and anti-inf lammatory factors reduced in mSOD1 G93A /RAG2 Ϫ/Ϫ and mSOD1 G93A /CD4 Ϫ/Ϫ mice, the messages for TNF-␣ and superoxide are increased, suggesting a decrease of protective factors and an increase in toxic molecules (Fig.  5 ). More importantly, BMT reconstituted mice with functional T cells and restored the neuroprotective factors, and also decreased the toxic and proinflammatory responses. These results suggest that CD4ϩ T cells directly or indirectly provide neuroprotection by modulating the trophic/cytotoxic balance of glia. Expanding this population may offer further protection in diverse forms of dominantly inherited chronic neurodegenerative diseases and may provide a novel target for critically needed therapies. Bone Marrow Transplantation. Donor bone marrow was obtained from 9 to 12 weeks old WT, mSOD1 G93A , or CCR2 Ϫ/Ϫ mice, and transplanted into the mSOD1 G93A /PU.1 Ϫ/Ϫ pups within 24 h of birth as previously described (6) . mSOD1 G93A /RAG2 Ϫ/Ϫ mice were sublethally ␥-irradiated (400 rads) and transplanted with WT, mSOD1 G93A , or RAG2 Ϫ/Ϫ donor-derived bone marrow. Details are provided in SI Methods.
Materials and Methods
Quantitative RT-PCR. RNA was isolated and purified from lumbar spinal cords, and quantitative RT-PCR was performed as previously described (19) . Technical details are given in SI Methods.
Immunohistochemistry and Antibodies. Spinal cord tissue was evaluated for the expression of CD3, CD4, CD8, CD11b, CD11c, CD19, CD40, CD68, MCH class II, and GFAP. Technical details are found in SI Methods.
Primary Microglia Cultures.
Primary microglial cultures were prepared from 8-to 9-day-old mice and treated with LPS as previously described (6) . Details are given in SI Methods.
Statistical Analyses. Data were analyzed using two-tailed Student's t test using Excel (Microsoft) software. Data are expressed as meanϮ SEM; P Ͻ 0.05 was considered statistically significant. Differences in onset and survival times were computed using Kaplan-Meier survival statistics (log-rank-sum test; Number Cruncher Statistical Systems, Kaysville, UT). Disease progression and the in vitro studies were analyzed using a one-way analysis of variance (ANOVA) with repeated measures (SigmaStat, Richmond CA). Differences between groups were analyzed using a two-way ANOVA (SigmaStat). Fig. 5 . The presence of T cells shifts the balance of microglial and astroglial responses from reduced protection and increased cytotoxicity to increased neuroprotection and decreased toxicity following BMT. 222Ͼ75% decrease; 2250 -75% decrease; 2, 0 -50% decrease; NC, no change; 1, 100 -500% increase; 11, 600 -1500% increase; and 111, 1600 -2500% increase; 1111, 2600 -5000% increase.
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Beers et al. 10.1073/pnas.0807419105 SI Materials and Methods SOD1 G93A Mice. All transgenic animals were bred and maintained in our animal facility (1, 2) . All mice were housed in microisolator cages within a modified pathogen-free barrier facility and had access to food and water ad libitum. All animal protocols were approved by the Methodist Research Institute's Institutional Animal Care and Use Committee in compliance with National Institutes of Health guidelines. Genomic tail DNA was isolated using a standard protocol.
Transgenic mice overexpressing the fALS associated G93A SOD1 mutation (G1H) (mSOD1 G93A ) were originally purchased from Jackson Laboratories (Bar Harbor, ME); strain designations were as follows: B6SJL-Tg(SOD1*G93A)1Gur/J and B6.Cg-Tg(SOD1*G93A)1Gur/J]. mSOD1 G93A mice on a B6/SJL genetic background had a mean survival time of 132 days, whereas mSOD1 G93A mice on a C57BL/6 genetic background survived for 160 days. Transgenic mSOD1 G93A animals were identified and copy number verified by quantitative PCR using the antisense and sense SOD1 oligonucleotides 5Ј-AATTTGT-GTCTACTCAGTCAA-3Ј and 5Ј-TCACTTTGATTGTT-AGTCGCG-3Ј, respectively. The PCR conditions for genomic tail DNA in a 50-l reaction using an Eppendorf Mastercycler gradient thermocycler (Westbury, NY) were as follows: 2 min at 94°C; then 35 cycles of 20 sec at 94°C, 20 sec at 60°C, and 30 sec at 72°C; then 2 min at 72°C and held at 4°C until the samples were run on a 1% agarose gel in 1X TAE buffer. All transgenic mice were housed in microisolator cages within a modified pathogenfree barrier facility and had access to food and water ad libitum. PU.1 Ϫ/Ϫ mice were bred with B6SJL-Tg(SOD1*G93A)1Gur/J, and RAG2 Ϫ/Ϫ and CD4 Ϫ/Ϫ mice were bred with B6.CgTg(SOD1*G93A)1Gur/J.
PU.1 Mice.
To prevent the possibility of graft-versus-host disease and/or alterations of onset and survival times resulting from differing genetic backgrounds, PU.1 heterozygous (PU.1 ϩ/Ϫ ) mice were first backcrossed with B6/SJL mice for 10 generations. PU.1 ϩ/Ϫ mice were then mated with mSOD1 G93A mice to produce PU.1 ϩ/Ϫ and mSOD1 G93A /PU.1 ϩ/Ϫ mice (2, 3). Finally, breeding mSOD1 G93A /PU.1 ϩ/Ϫ with PU.1 ϩ/Ϫ generated PU.1
and mSOD1 G93A /PU.1 Ϫ/Ϫ mice. Within 12 h of birth, PU.1 litters were injected with antibiotic (Baytril, Bayer HealthCare). Giemsa staining was used to identify the PU.1 Ϫ/Ϫ pups from a drop of tail blood smeared onto a glass slide and dried for 10 min at room temperature (RT). The Giemsa stain (Sigma) covered the blood smear and incubated for 5 min at RT. Phosphate-buffered saline (PBS) was added to the slide just to cover and incubated for 10 min at RT. The slides are briefly washed and dehydrated in 70% ethanol. The slides were then air dried and cover slipped using glycerol and were immediately examined. The presence or absence of the PU.1 gene was then confirmed by PCR (Eppendorph Mastercycler) using 250 ng tail DNA and using Eppendorf TaqDNA polymerase according to the manufacturer's instructions. The following primers were used: A) forward PUKO, 5Ј-GCCCCGGATGTGCTTCCCTTATCAAACC-3Ј; B) reverse 920, 5Ј-TGCCTCGGC-CCTGGGAATGTC-3Ј; C) reverse 0.Neo.1, 5Ј-CGCACGGGTGT TGGGTCGT T TG-TTGG-3Ј. The A and B primers were used to identify mice with the WT PU.1 gene, and the A and C primers were used to identify mice with the PU.1 deletion. The PCR protocol was as follows: 92°C for 2 min; [denatured at 92°C for 1 min, annealed at 65°C for 2 min, and extended at 72°C for 3 min] for 45 cycles; then 72°C for 7 min, and finally held at 4°C. The PCR products were resolved by 1.0% agarose/ethidium bromide gel electrophoresis and photographed under UV illumination. PU.1 Ϫ/Ϫ mice received daily antibiotic injections for the first 3 weeks after birth. PU.1 Ϫ/Ϫ , PU.1 ϩ/Ϫ , and WT mice were weighed and observed for signs of motoneuron disease daily. Transgenic mSOD1 G93A mice animals were identified by quantitative PCR to ensure mSOD1 G93A transgene copy numbers remain stable.
RAG2 Mice. RAG2
Ϫ/Ϫ mice were initially bred with B6.CgTg(SOD1*G93A)1Gur/J for at least eight generations. The presence or absence of the RAG2 gene was determined by PCR (Eppendorf Mastercycler) using 250 ng of tail DNA and using Eppendorf TaqDNA polymerase according to the manufacturer's instruction. The following primers were used: Rag A) 5Ј-GGGAGGACACTCACTTGC-CAG-3Ј and Rag B) 5Ј-AGTCAGGAGTCTCCATCTCAC-3Ј and Neo C) 5Ј-CG-GCGG-GAGAACCTGCGTGCAA-3Ј. Homozygotic mice will have one 350 bp band. Heterozygotic mice will have 350 and 263 bp bands. Wild-type mice will have one 263 bp band. The PCR protocol was: 95°C for 15 min (denatured at 94°C for 45 sec, annealed at 55°C for 1 min, and extended at 72°C for 1 min) for 35 cycles, then 72°C for 7 min, and finally held at 4°C. The PCR products were resolved by 1.0% agarose/ethidium bromide gel electrophoresis and photographed under UV illumination. Transgenic mSOD1 G93A mice animals were identified by quantitative PCR to ensure mSOD1 G93A transgene copy numbers remain stable. After the initial cross, mSOD1 G93A /RAG2 ϩ/Ϫ mice were bred with RAG2 Ϫ/Ϫ mice that enabled a direct comparison of mSOD1 G93A /R AG2 Ϫ/Ϫ mice with their mSOD1 G93A /RAG2 ϩ/Ϫ littermates.
CD4 Mice. CD4
Ϫ/Ϫ mice were initially bred with B6.CgTg(SOD1*G93A)1Gur/J for at least 8 generations. The presence or absence of the CD4 gene was also determined by PCR (Eppendorf Mastercycler) using 250 ng of tail DNA and using Eppendorf TaqDNA polymerase according to the manufacturer's instruction. The following primers were used: CD4 A) 5Ј-CCTCTTGGTTAATGGGGG-AT-3Ј and CD4 B) 5Ј-TTTTTCTGGTCCAGGGTCAC-3Ј and CD4 C) 5Ј-GTGTT-GGG-TCGTTTGTTCG-3Ј. Knockout mice will have one band 225 bp; heterozygotic mice will have bands 380 and 225 bp; and wild-type mice will have one band 380 bp. The PCR protocol was as follows: 94°C for 3 min; [denatured at 94°C for 30 sec, annealed at 57°C for 1 min, and extended at 72°C for 1 min] for 35 cycles; then 72°C for 2 min, and finally held at 4°C. The PCR products are resolved by 1.0% agarose/ethidium bromide gel electrophoresis and photographed under UV illumination. Transgenic mSOD1 G93A mice animals were identified by quantitative PCR to ensure mSOD1 G93A transgene copy numbers remain stable. After the initial cross, mSOD1 G93A /CD4 ϩ/Ϫ mice were bred with CD4 Ϫ/Ϫ mice to enable a direct comparison of mSOD1 G93A /CD4
Ϫ/Ϫ mice with their mSOD1 G93A /CD4 ϩ/Ϫ littermates.
Bone Marrow Transplantation. The donor bone marrow was obtained from 9-to 12-week-old WT, mSOD1 G93A , or CCR2
Ϫ/Ϫ mice and was transplanted into the mSOD1 G93A /PU.1 Ϫ/Ϫ pups within 24 h of birth, as previously described (1) . mSOD1 G93A / RAG2 Ϫ/Ϫ mice were sublethally ␥-irradiated (400 rads) and transplanted with WT, mSOD1 G93A , or RAG2 Ϫ/Ϫ donor-derived bone marrow. Briefly, the donor mice were lethally anesthetized and their femurs removed under sterile conditions. The bone marrow was flushed out of the femurs with Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal calf serum. The hematopoietic cells were successively passed through 18-, 21-, 23-, and 25-gauge needles. The cells were then pelleted at 250 g for 10 min, washed with 5 ml DMEM without FCS, and resuspended at 2 ϫ 10 8 cells/ml DMEM without FCS. Using a 27-gauge needle, a 50-l aliquot (1 ϫ 10 7 cells per mouse) was injected i.p. into mSOD1 G93A /PU.1 Ϫ/Ϫ mice, or a 200-l aliquot (3 ϫ 10 7 cells per mouse) was injected i.v. via the tail vein for mSOD1 G93A /RAG2 Ϫ/Ϫ mice.
Quantitative RT-PCR. RNA was isolated from homogenized flashfrozen murine lumbar spinal cords using TRIzol (Gibco) and purified using RNeasy (Qiagen) according to the manufacturer's recommendations. The concentrations were determined spectrophotometrically (NanoDrop 1000). Quantitative RT-PCR was performed on 10 ng mRNA using an iQ5 Multicolor Real-Time PCR Detection System (BioRad), all normalized with ␤-actin. The iScript One-step RT-PCR kit with SYBR Green (BioRad) or QuantiTect SYBR Green RT-PCR kit (Qiagen) was used to perform the quantitative RT-PCR according to the manufacturer's instructions. The primers sets were tested over a temperature gradient for amplification efficiency and specificity, and verified over 3 orders of magnitude for linearity. The relative expression levels of each mRNA were calculated using the ⌬⌬Ct method normalizing to ␤-actin or GAPDH and relative to the control samples. The presence of one product of the correct size was verified by 1.5% agarose gel electrophoresis and by melting curve analyses containing a single melt curve peak. All samples were run in duplicate and were tested in a minimum of three separate experiments.
Immunohistochemistry and Antibodies. Lethally anesthetized mice were first perfused with ice-cold PBS and then ice-cold 3% paraformaldehyde. Spinal cords were removed, postfixed overnight in 3% paraformaldehyde, and placed in 30% sucrose. Sections 30 m thick were cut from fixed spinal cord tissue, washed three times in PBS, and blocked for endogenous peroxidase activity (0.3% H 2 O 2 in distilled water for 30 min). The sections were pretreated with 5% normal goat serum (Vector Laboratories, Burlingame, CA) for 1 h at RT to block nonspecific IgG binding. The CD3, CD4, CD8, CD11b, CD19, CD40, CD68, and MCH class II were rat anti-mouse, CD11c was hamster anti-mouse Ab (Serotec Inc., Raleigh, NC; 1:500, 1:500, 1:500, 1:1000, 1:500, 1:2000, 1:2000, 1:500, and 1:500 dilutions, respectively), and GFAP was rabbit anti-bovine (DAKO; 1:50,000) The primary Ab were diluted in PBS containing 5% normal goat serum and incubated with the sections overnight at 4°C. As a negative control, the primary Ab were omitted during the reaction. After rinsing in PBS, the sections were incubated with biotinylated goat anti-rat IgG (1:200 dilution in PBS containing 5% normal goat serum, Serotec), biotinylated goat anti- Primary Microglia Cultures. Primary microglial cultures were prepared from 8-to 9-day-old mice and treated with LPS, as previously described (4) . Briefly, after removal of the meninges, the cortexes were minced and digested with 0.25% trypsin and 0.01% DNase. After mechanical dissociation, the cells were resuspended in SATO's medium supplemented with 10% FBS and seeded in 150 cm 2 flasks at a density of 2 ϫ 10 7 cells per flask. Twenty-four hours later, the medium was changed. After the cells were incubated at 37°C with 5% CO 2 for 1 week, the medium was changed. The flasks were then shaken at 100 rpm for 15 h. More than 95% of the floating cells were microglia, as determined by OX42 (Chemicon, Temecula, CA) immunocytochemical staining. Microglia monocultures were plated at a density of 20,000 cells per well. Microglia were activated with LPS. Microglial activation was determined by measuring the levels of TNF-␣ and IL-1␤ in the culture media using a sandwich enzyme-linked immunosorbent assay (ELISA; R&D Systems). A 5-l quantity of medium from a microglia culture was incubated with 50 l Assay Diluent RD1Ϫ41 in the TNF-␣ assay plate for 2 h at RT. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for rat TNF-␣ was added to the wells. Following the addition of the peroxidase substrate solution, the enzyme-reactive color product was detected by a microplate reader set to 450 nm with a wavelength correction set to 540 nm. The same procedure was used for IL-1␤.
Statistical Analyses. Data were analyzed using two-tailed Student's t test using Excel (Microsoft) software. Data are expressed as mean Ϯ SE.; P Ͻ 0.05 was considered statistically significant. Differences in onset and survival times were computed using Kaplan-Meier survival statistics (log-rank-sum test; Number Cruncher Statistical Systems). Disease progression and the in vitro studies were analyzed using one-way ANOVA with repeated measures (SigmaStat). Differences between groups were analyzed using a two-way ANOVA (SigmaStat). (K) Mouseϩhuman SOD1 was elevated in all genotypes of mSOD1 G93A mice compared with WT mice. 1, WT mice; 2, mSOD1 G93A mice; 3, mSOD1 G93A /RAG2 ϩ/Ϫ mice;
4, mSOD1 G93A /RAG2 Ϫ/Ϫ mice; 5, mSOD1 G93A /RAG2 Ϫ/Ϫ mice ϩ BMT; and 6, mSOD1 G93A /CD4 Ϫ/Ϫ mice. n ϭ 3 for all groups of mice. n.s., not significant. * , Decreased compared with mSOD1 G93A or mSOD1 G93A /RAG2 ϩ/Ϫ mice, P Ͻ 0.05; #, not different from mSOD1 G93A /RAG2 ϩ/Ϫ mice; ‡, not different from mSOD1 G93A /RAG2 Ϫ/Ϫ mice; ** , increased compared with mSOD1 G93A or mSOD1 G93A /RAG2 ϩ/Ϫ mice, P Ͻ 0.05; ##, decreased compared with mSOD1 G93A /RAG2 Ϫ/Ϫ mice, P Ͻ 0.05.
